Trial is approved for stem cell treatment for dry AMD

02/3/2012 | Wall Street Journal, The

The FDA is permitting StemCells to conduct a safety and efficacy trial of therapeutic candidate HuCNS-SC cells among patients with dry age-related macular degeneration, or AMD. Last year, testing of the adult stem cell treatment for a rare childhood brain disorder was halted because of a lack of qualified participants.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA